U.S. Markets closed

Xenetic Biosciences Oncology Phase II Trial in Process, Pipeline Overview

NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Xenetic Biosciences, Inc. (XBIO), a clinical-stage biopharmaceutical company. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer.

On Monday, August 13, 2018, XBIO shares surged to an intra-day high of $4.60, a 44% jump from the previous Friday's close. Share volume exceeded the daily average by a factor of ten.

About XBIO-101 and the Polyzen drug development platform READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/xenetic-biosciences/

In 2018, an estimated 63,000 cases of endometrial cancer will be diagnosed in the U.S., and an estimated 11,000 disease-associated deaths will occur. While the incidence and mortality of endometrial cancer (EC) have been steadily increasing in the United States, the number of FDA-approved treatment options for late-stage EC remains extremely limited. In particular, there is a significant unmet need for therapies to treat advanced, recurrent, or metastatic EC.

Details of the company Q2 earnings release and Phase II clinicals info READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/xenetic-biosciences/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source